Benicar

Benicar

Benicar (olmesartan medoxomil) was approved by the Food and Drug Administration in 2002 to treat high blood pressure (hypertension). It is a member of the “angiotensin receptor blockers” (ARB) class of anti-hypertensive medications.

Benicar was developed by Sankyo Co., a Japanese pharmaceutical company in 1995 who merged with Daiichi Pharmaceuticals in 2005 to become the second largest pharmaceutical manufacturer in Japan, Daiichi Sankyo Company, Limited. Benicar is manufactured and marketed in the US by the subsidiary Daiichi Sankyo Inc. (DSI).

Daiichi Sankyo sells pharmaceutical, medical, and agricultural products in 50 countries and reported $11 billion in total worldwide revenue in 2013. Benicar is among the top 100 selling drugs in the US and is sold at a rate of 11 million prescriptions bringing $3.1 billion in worldwide revenue for Daiichi.

The active ingredient in Benicar (olmesartan) is also one ingredient in combination high-blood pressure medications such as Benicar HCT (olmesartan with hydrochlorothiazide, a diuretic), Azor (olmesartan with amlodipine, a calcium channel blocker), and Tribenzor (olmesartan with hydrochlorothiazide and amlodipine).

Unlike other members of the ARB class of blood pressure medications, Benicar has been shown to cause a serious gastrointestinal side effect known as “sprue-like enteropathy” which can cause severe, chronic diarrhea and significant weight loss and is similar to symptoms of celiac disease. Multiple lawsuits have been filed against Daiichi Sankyo for serious injury caused by Benicar and more are expected to follow.

What is Benicar?

Benicar is an inhibitor of the angiotensin-II receptor, also known as an angiotensin receptor blocker (ARB) or a “sartan” because of the generic name olmesartan. The ARB class of anti-hypertensives work by blocking the activity of angiotensin-II in the cardiovascular system.

Angiotensin-II is a product of the liver which is intended to regulate the blood pressure system. When the protein is produced by the liver, it has a vasoconstrictive effect that tightens the blood vessels and raises blood pressure. Increased blood pressure makes the heart work harder to pump blood through the body and can also damage other organs such as the kidneys.

Blocking angiotensin-II helps to lower the blood pressure by stopping vasoconstriction. This helps the blood flow more freely through the vessels and decreases the work the heart must do to supply the body with blood and oxygen.

Benicar was shown to cause severe gastrointestinal illness in some patients who took the medication in a research connection discovered by the Mayo Clinic in 2012. The Mayo Clinic notified the FDA about a high occurrence of “sprue-like enteropathy” that had symptoms similar to Celiac disease with side effects such as severe and chronic diarrhea, lack of nutrient absorption and extreme weight loss. All of the observed patients had tested negative for Celiac disease but all had taken Benicar. Most patients who were identified as Benicar related illnesses improved after discontinuing the medication but some did not. The rate of non-Celiac or unclassified sprue occurrence may be as high as 30 percent.

Following the Mayo Clinic’s report, the FDA added a warning to prescribing information of Benicar in July of 2013. Benicar also has a black-box warning regarding the risk of birth defects in women who are pregnant while taking the medication.

Benicar and other related medications containing olmesartan are the only member of the ARB class of medications that have caused the GI side effects, many patients have sued the manufacturer, Daiichi Sankyo for injuries, hospitalization and permanent damage caused by Benicar.

Benicar Side Effects

Benicar and medications containing olmesartan have a number of side effects. Like most medications, many of these side effects are mild to moderate but may have a negative impact on the patient’s quality of life. In other cases, however side effects are more severe and may be life-threatening.

Common side effects of Benicar include:

  • Rash
  • Hair loss
  • Arthritis
  • Nausea and vomiting
  • Irregular heart beat
  • Chest pain
  • Angioedema (swelling of the skin)
  • Liver and kidney impairment

Benicar Severe Side Effect

Benicar may also cause a much more severe adverse event affecting the gastrointestinal system. Benicar has been shown to cause sprue-like enteropathy in some patients. Sprue-like enteropathy causes severe symptoms that are similar to Celiac disease but the patient does not have and will test negative for Celiac disease. GI symptoms caused by Benicar include:

  • Severe abdominal pain
  • Severe and chronic diarrhea
  • Nutrient malabsorption
  • Significant weight loss

Doctors will often test for Celiac disease when a patient reports these symptoms. Unfortunately, in some cases even if Benicar is discontinued, the patient will continue to suffer from the gastrointestinal illness and they will not respond to traditional Celiac regimens. Some patients have suffered with the illness for multiple years, seen multiple physicians and may have been hospitalized for the illness.

In addition, some patients may have permanent injury to the gastrointestinal system with a condition known as “villous atrophy” which results in a permanent lack of ability of the GI system to absorb nutrients. Some cases of villous atrophy may be so severe that the small intestine allows larger undigested food particles to pass into the blood stream. These particles can cause a severe immune reaction, resulting in body-wide inflammation and a number of food sensitivities.

Benicar also has a black-box warning (the most severe warning a medication can have) regarding the possibility of birth defects in women who take the medication while they are pregnant. Pregnant women should not take Benicar or products containing olmesartan due to injury of death of the developing fetus.

Benicar Lawsuits

Benicar InfographicA number of patients who were injured by taking Benicar have sued the manufacturer, Daiichi Sankyo Inc. Some patients have undergone years of treatment with extreme pain and physical debility. They may have been required to visit multiple physicians to seek relief from intestinal complaints and may have required treatment for other health conditions caused by the side effects of the medication such as nutrient malabsorption and weight loss. Some patients have also been hospitalized to treat complications and have had permanent injury or disability such as the failure of the digestive system, requiring a permanent feeding tube.

Benicar clinical trials were only performed for 3 months, even though most anti-hypertensives are prescribed for much longer than 6 months and may be given for years. In addition, independent reviews of adverse event data has shown that Daiichi Sankyo should have been aware of the increased GI complaint rate; however Daiichi failed to include this information in marketing material.

Daiichi Sankyo is reported to have spent approximately $1 billion in aggressive promotions claiming Benicar was superior to other ARBs with an increased safety and efficacy profile. The manufacturers of Benicar, Daiichi Sankyo have been warned twice by the FDA for making false or misleading claims about the medication indicating that claims were unsubstantiated and risks were not included in marketing materials.

Multiple lawsuits have been filed against Daiichi Sankyo for aggressive promotion, deceptive advertising, and failure to warn the medical community and patients about the increased risk of side effects and permanent injury. The company has been accused of placing profits above patient safety and many more Benicar lawsuits are expected.

Patients who have been injured by Benicar or other medications containing olmesartan may be eligible for actual damages (medical costs, permanent injury) and punitive damages (to punish the company).

View Sources
  1. Berkrot, B., (11 June 2010), Update 2-FDA looking into death risk from Daiichi’s Benicar, Reuters, Accessed on 03 September 2014 http://www.reuters.com/article/2010/06/11/fda-benicar-idUSN1113920620100611
  2. Drugs.com (2014) Top 100 Drugs of 2013, Drugs.com, Accessed on 03 September 2014 http://www.drugs.com/stats/top100/2013/sales
  3. DSI, (2014), Benicar Prescribing Information, Daiichi Sankyo Inc., Accessed on 03 September 2014 http://www.benicarhcp.com/
  4. Food and Drug Administration (03 July 2013), FDA Drug Safety Communication: FDA approves label changes to include intestinal problems (sprue-like enteropathy) linked to blood pressure medicine olmesartan medoxomil, U.S. FDA, Accessed on 03 September 2014 http://www.fda.gov/drugs/drugsafety/ucm359477.htm
  5. Food and Drug Administration (2014), Postmarket Drug Safety Information for Patients and Providers: olmesartan, U.S. FDA, Accessed on 03 September 2014 http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm215245.htm
  6. Kaiser, C., (03 July 2013), FDA Adds GI Warning to Benicar Label, MedPage Today, Accessed on 03 September 2014 http://www.medpagetoday.com/Cardiology/Hypertension/40278
  7. Reuters (02 September 2014), Daiichi Sankyo Co Ltd, Reuters Financials, Accessed on 03 September 2014 http://www.reuters.com/finance/stocks/financialHighlights?rpc=66&symbol=4568.T
  8. Rubio-Tapia, A., et al, (25 June 2010), Severe Spruelike Enteropathy Associated With Olmesartan, Mayo Clinic Proceedings, Accessed on 03 September 2014 http://www.mayoclinicproceedings.org/article/S0025-6196%2812%2900558-7/fulltext
  9. Ryan, G., (25 February 2014) Firms Kick Off Benicar Diarrhea Suits Against Daiichi. Law360, Accessed on 03 September 2014 http://www.law360.com/newjersey/articles/513068/firms-kick-off-benicar-diarrhea-suits-against-daiichi
  10. Sanders, L., (07 February 2014), Think Like a Doctor: Stomach Bug Solved!, NY Times Well Blog, Accessed on 03 September 2014 http://well.blogs.nytimes.com/2014/02/07/think-like-a-doctor-stomach-bug-solved/?_php=true&_type=blogs&_php=true&_type=blogs&_r=1
  11. Staton, T., (7 May 2014) 10 big brands keep pumping out big bucks, with a little help from price hikes, Fierce PharmaMarketing, Accessed on 03 September 2014 http://www.fiercepharmamarketing.com/story/10-big-brands-keep-pumping-out-big-bucks-little-help-price-hikes/2014-05-07